Impact of Virtual Care on Chronic Kidney Disease Management
The Peterson Health Technology Institute (PHTI) recently published a report concluding that virtual solutions for managing chronic kidney disease (CKD) do not consistently improve disease outcomes or significantly reduce costs compared to traditional care models.
This evaluation reviewed several prominent organizations offering virtual care, including DaVita Integrated Kidney Care and Strive Health, and utilized data from the Centers for Medicare & Medicaid Services' Kidney Care Choices model. Despite extensive analysis of patients with CKD in stages 3 to 5, the study found no substantial evidence that virtual care slowed disease progression or enhanced medication utilization.
Key Findings from the Study
One crucial finding was the lack of impact on progression to end-stage kidney disease, a critical measure for assessing chronic kidney disease treatments. Specifically, the study noted that interventions did not significantly affect the annual decline in estimated glomerular filtration rate (eGFR). Furthermore, there were minimal differences in the use of kidney-protective drugs, such as ACE inhibitors and SGLT2 inhibitors, between program participants and non-participants.
| Organization | Key Outcome | Evidence Strength |
|---|---|---|
| Strive Health | Reduced readmissions, slower eGFR decline | Strong |
| DaVita IKC, Evergreen, etc. | No significant clinical evidence | Weak |
Implications for the Insurance Sector
For insurance professionals, these findings underscore challenges in managing CKD within value-based care frameworks. The modest financial benefits highlighted—an estimated annual savings of just $53 per member for Traditional Medicare—suggest limited economic incentive without significant improvements in patient outcomes. Furthermore, the heavily data-driven nature of these findings provides focal points for carriers aiming to refine their strategies regarding chronic disease management.
Challenges Facing Virtual CKD Programs
The PHTI report points to several barriers to the efficacy of virtual care programs. Among these are difficulties in patient incentivization and widespread unawareness of CKD, with nearly 87% of affected adults oblivious to their condition. As insurers and healthcare providers strategize to overcome these challenges, a revised contractual focus on specific patient milestones, like timely kidney testing and the primary-care initiation of protective medications, might offer potential solutions.
As observed, value-based models require comprehensive adjustments to become truly effective. Therefore, insurance professionals will need to remain vigilant about evolving CKD management strategies in collaboration with healthcare providers, ensuring both patient health outcomes and financial sustainability are prioritized in these emerging frameworks.